Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 809840, 5 pages
http://dx.doi.org/10.1155/2015/809840
Case Report

Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland

1Institute of Hematology and Transfusion Medicine, Ulica Indiry Gandhi 14, 02-776 Warsaw, Poland
2The Binding Site Group Ltd., 8 Calthorpe Road, Birmingham B151QT, UK

Received 16 September 2015; Revised 3 December 2015; Accepted 7 December 2015

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2015 Maria Kraj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Landgren, R. A. Kyle, R. M. Pfeiffer et al., “Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study,” Blood, vol. 113, no. 22, pp. 5412–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl, “A monoclonal gammopathy precedes multiple myeloma in most patients,” Blood, vol. 113, no. 22, pp. 5418–5422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. J. Morgan, B. A. Walker, and F. E. Davies, “The genetic architecture of multiple myeloma,” Nature Reviews Cancer, vol. 12, no. 5, pp. 335–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Korde, S. Y. Kristinsson, and O. Landgren, “Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM): novel biological insights and development of early treatment strategies,” Blood, vol. 117, no. 21, pp. 5573–5581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Lohr, P. Stojanov, S. Carter et al., “Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy,” Cancer Cell, vol. 25, no. 1, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Melchor, A. Brioli, C. P. Wardell et al., “Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma,” Leukemia, vol. 28, no. 8, pp. 1705–1715, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Ayliffe, F. E. Davies, D. de Castro, and G. J. Morgan, “Demonstration of changes in plasma cell subsets in multiple myeloma,” Haematologica, vol. 92, no. 8, pp. 1135–1138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Ayliffe, J. Behrens, S. Stern, and N. Sumar, “Association of plasma cell subsets in the bone marrow and free light chain concentrations in the serum of monoclonal gammopathy patients,” Journal of Clinical Pathology, vol. 65, no. 8, pp. 758–761, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Brioli, L. Melchor, M. Cavo, and G. J. Morgan, “The impact of intra-clonal heterogeneity on the treatment of multiple myeloma,” British Journal of Haematology, vol. 165, no. 4, pp. 441–454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Brioli, H. Giles, C. Pawlyn et al., “Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma,” Blood, vol. 123, no. 22, pp. 3414–3419, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. R. Hobbs, M. T. Drayson, K. Sharp, S. Harding, A. R. Bradwell, and G. P. Mead, “Frequency of altered monoclonal protein production at relapse of multiple myeloma,” British Journal of Haematology, vol. 148, no. 4, pp. 659–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kühnemund, P. Liebisch, K. Bauchmüller et al., “‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 3, pp. 477–484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo et al., “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. V. Rajkumar, J.-L. Harousseau, B. Durie et al., “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1,” Blood, vol. 117, no. 18, pp. 4691–4695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. M. Boyle, G. Fouquet, S. Guidez et al., “IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma,” Cancer, vol. 120, no. 24, pp. 3952–3957, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Ludwig, D. Milosavljevic, N. Zojer et al., “Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients,” Leukemia, vol. 27, no. 1, pp. 213–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Young, H. Ludwig, N. Zojer, D. Milosavljevic, and S. Harding, “Use of heavy/light chain (HLC) and free light chain (FLC) ratios for monitoring oligosecretory multiple myeloma patients,” Clinical Lymphoma, Myeloma & Leukaemia, vol. 13, supplement 1, p. 236a, 2013. View at Google Scholar
  18. H. Ludwig, J. S. Miguel, M. A. Dimopoulos et al., “International Myeloma Working Group recommendations for global myeloma care,” Leukemia, vol. 28, no. 5, pp. 981–992, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. L. J. Donato, S. R. Zeldenrust, D. L. Murray, and J. A. Katzmann, “A 71-year-old woman with multiple myeloma status after stem cell transplantation,” Clinical Chemistry, vol. 57, no. 12, pp. 1645–1648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Katzmann, M. A. V. Willrich, M. C. Kohlhagen et al., “Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays,” Clinical Chemistry, vol. 61, no. 2, pp. 360–367, 2015. View at Publisher · View at Google Scholar · View at Scopus